VarmX is a clinical stage company developing drugs that reverse the action of direct acting oral anticoagulants (DOACs).The lead program is a recombinant protein, VMX-C001, that addresses the need of a safe and more efficacious antidote against excessive bleeding caused by FXa DOACs. 

Location: Leiden, the Netherlands

Sound contact: Casper Breum (Board Director) and Philip Brainin (Board Observer)

News: VarmX to Present New Data at the 2022 ISTH Congress

Read an interview with Jan Öhrström, CEO & Founder: From toxin to remedy, and operating room to the boardroom



* indicates required